Biogaia Protectis Baby Drops+D3 5ml

Clinically studied and proven as a dietary treatment for the treatment of 1st trimester colic in infants. Dosage: 5 drops once daily (contains 108 CFUs L.reuteri ProTectis® and 400IU of vitamin D). Each vial is sufficient for one month. Suitable for the prevention of gastrointestinal disorders caused by antibiotics (diarrhea, abdominal pain, flatulence) in infants and toddlers. Dosage: 5 drops once (containing 108 CFUs L.reuteri ProTectis®) 1 hour after antibiotic administration. Each vial is sufficient depending on the antibiotic administration per 24 hours. Suitable for the treatment of gastrointestinal disorders caused by antibiotics (diarrhea, abdominal pain, flatulence) in infants and toddlers. Dosage: 10 drops once (contains 2x108 CFUs L.reuteri ProTectis®) 1 hour after each antibiotic administration. Each vial is sufficient depending on the antibiotic administration per 24 hours. It is also recommended for the prevention of functional gastrointestinal disorders (colic, constipation, reflux) in infants during the first 6 months of life. Dosage: 5 drops once daily (containing 108 CFUs L.reuteri ProTectis®) for the first three months. Each vial is sufficient for one month. Absolutely safe for babies, toddlers and children Clinically proven to reduce colic in infants Clinically proven to prevent antibiotic-induced gastrointestinal disorders Clinically proven to prevent functional gastrointestinal disorders Easy to administer to infants and children Does not affect breastfeeding or the taste of food Vitamin D The recommended dosage of 5 drops daily provides 400 IU of vitamin D based on the recommendations of the American Academy of Pediatrics (AAP) and the European Food Safety Authority (EFSA). A daily intake of 400IU of vitamin D is recommended as a dietary treatment for proper bone development in children. Exclusively breastfed infants (for as long as breastfeeding lasts) Premature infants (for the 1st year of their life) The probiotic L.reuteri Protectis® BioGaia® ProTectis + D3 drops contain L.reuteri Protectis®, the patented probiotic bacterium of the company BioGaia Sweden. Originally isolated from breast milk, it is one of the most studied probiotics worldwide and the most studied in infants and children. Its safety and efficacy have been proven in 108 clinical studies (last update 12/2014). L.reuteri Protectis® fully meets the WHO requirements for probiotics. In an in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract for five days, L. reuteri Protectis® was one of only three strains that survived. This was also confirmed in vivo, when its intake by healthy humans led to significant colonization of the stomach, duodenum and ileum. L. reuteri Protectis® colonizes the entire gastrointestinal tract, prevents the growth of harmful microorganisms, activates the immune system and improves gastrointestinal function. Indicative clinical studies with the probiotic L.reuteri Protectis® In an open study published in the journal Pediatrics by Savino (2007), the effectiveness of L.reuteri Protectis® was demonstrated in relation to simethicone: 74% reduced crying time with administration of L. reuteri Protectis® compared to 26% reduction with administration of the chemical simethicone In a study published in the journal Pediatrics by Savino (2010), the effectiveness of L.reuteri Protectis® was demonstrated compared to placebo: 74% reduced crying time with L. reuteri Protectis® compared to 38% reduction with placebo after one week of treatment In a new, independent study published in the journal Pediatrics by Szajewska (2012), the effectiveness of L.reuteri Protectis® was confirmed compared to placebo: 75% success in treatment within two weeks with L. reuteri Protectis® compared to 18% in the placebo group Significantly improved family quality of life in the L. reuteri Protectis® group A new, independent study published in the journal JAMA Pediatrics by Indrio (2014) confirmed the possibility of preventing functional gastrointestinal disorders during the 1st trimester of life with L.reuteri Protectis® compared to placebo.